Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
IBER.WS
IBER.WS was delisted on the 15th of February, 2023.
30 hedge funds and large institutions have $3.74M invested in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
43% more funds holding
Funds holding: 21 → 30 (+9)
19% more capital invested
Capital invested by funds: $3.14M → $3.74M (+$598K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$112K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$70.8K |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$55.9K |
| 4 |
Walleye Capital
New York
|
+$30.9K |
| 5 |
Walleye Trading
New York
|
+$22.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$14.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.04K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
26
Ayrton Capital
Westport,
Connecticut
| $15K | +$16.1K | +28,393 | New |
|
|
PI
27
PEAK6 Investments
Chicago,
Illinois
| $14K | – | – | – |
|
|
TCM
28
Tegean Capital Management
New York
| $12K | +$13K | +22,855 | New |
|
|
PCM
29
Prelude Capital Management
New York
| $10K | +$227 | +400 | +2% |
|
30
Capstone Investment Advisors
New York
| $7K | – | – | – |
|
IBER.WS Hedge Fund Activity: Q4 2021 in Review
30 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) for Q4 2021, worth a combined $3.74M — up 19% from $3.14M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new IBER.WS positions and 0 closed out — a net gain of 10 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Shaolin Capital Management, opening a new position worth an estimated $112K. The largest seller was Polar Asset Management Partners, cutting an estimated $14.9K.
- 30 institutional investors held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) as of Q4 2021, up from 21 in Q3 2021.
- Funds reported $3.74M of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share stock for Q4 2021, up 19% quarter-over-quarter.
- 10 funds opened new Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share positions in Q4 2021 and 0 closed out, a net change of +10 holders.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share buyer in Q4 2021 was Shaolin Capital Management, an estimated $112K added.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share seller in Q4 2021 was Polar Asset Management Partners, an estimated $14.9K sold.
Based on aggregated 13F filings for Q4 2021.